FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. KFY
5. ABBV
6. MU
7. DPZ
8. NAVN
9. DFTX
10. NVEC

Go back to FDA Advisory Committee Recommends the Approval of Baricitinib 2mg, but not 4mg, for the Treatment of Moderately-to-Severely Active Rheumatoid Arthritis

Incyte (INCY) PT Raised to $77 at RBC Capital; 'Base Case'

April 24, 2018 6:29 AM EDT

RBC Capital raised its price target on Incyte (NASDAQ: INCY) to $77.00 (from $75.00) while maintaining a Outperform rating after the FDA's AdComm voted favorably for 2mg dose of baricitinib, but unfavorably for 4mg dose given VTE signals.

"We view this as the base case,... More